

EPHMRA
ANATOMICAL CLASSIFICATION
GUIDELINES 2024

Section B

Changed Classes/Guidelines

Final Version

Date of issue: 20th December 2023

| | | |
|-------------|--|-------|
| A6 | DRUGS FOR CONSTIPATION AND BOWEL CLEANSERS | r2014 |
| | Includes laxatives and other products for constipation. Products that are both laxatives and bowel cleansers are classified in the appropriate laxative class. For the classification of products indicated for irritable bowel syndrome with constipation (IBS-C) see A3G. | |
| A6A | DRUGS FOR CONSTIPATION | r2014 |
| A6A1 | Faecal softening laxatives | r2015 |
| | Includes products containing softening laxatives such as liquid paraffin or docusate sodium. Combinations of faecal softening laxatives with osmotic laxatives are classified here. Combinations with bulk-forming laxatives are classified in A6A3. Combinations with stimulant laxatives are classified in A6A2. | |
| | For castor oil products see A6A2. Glycerol suppositories are classified in A6A9. | |
| A6A2 | Stimulant laxatives | r2013 |
| | Includes products containing laxatives that have a stimulant effect on the intestinal membrane and peristalsis. Many of these are herbal, eg senna, or of herbal origin (anthraquinones, emodines, glycosides, etc). This group also includes phenolphthalein-derivatives, bisacodyl, and sodium picosulphate when used as a laxative. Products containing a stimulant laxative in combination with other laxative substances (except bulk-forming) are classified here. | |
| A6A3 | Bulk-forming laxatives | r2013 |
| | Includes products containing substances such as bran, ispaghula, methylcellulose, sterculia. Products containing a bulk-forming laxative in combination with other types of laxative are classified here. | |
| A6A4 | Enemas | R2015 |
| | Includes all products for constipation in enema form. Other rectal forms for constipation are classified as appropriate in the other constipation classes. Glycerol suppositories and effervescent suppositories are classified in A6A9. | |
| | Combination packs containing an enema and another form are classified according to the other form. | |
| A6A5 | Peripheral opioid antagonist laxatives | I2024 |
| | Includes products containing peripheral opioid receptor antagonist laxatives for the treatment of opioid-induced constipation (OIC). Substances include methylnaltrexone, naldemedine, naloxegol, etc. | |
| | Products containing naloxone for opioid dependence are classified in N7F. | |

| | | |
|------------|---|-------|
| A8 | ANTI OBESITY PREPARATIONS, EXCLUDING DIETETICS | |
| A8A | ANTI OBESITY PREPARATIONS, EXCLUDING DIETETICS Includes all centrally- and peripherally-acting substances indicated for obesity, eg amphetamines, cannabinoid receptor antagonists (CB1), and lipase inhibitors. Combinations of these substances with laxatives or dietetics are included in A8A when the specific indication is obesity. Herbal products are also included. This class excludes dietary products (nutrients) used to aid in weight reduction (see V6A). Chitin-based products are classified in V6A when used in weight reduction. Combinations of anti-obesity drugs with antidiabetics where the aim is to treat both the diabetes and the obesity are classified in A10X1. Products containing GLP-1 agonists, or dual GIP/GLP-1 agonists, for weight management only are classified here. Products containing GLP-1 agonists, or dual GIP/GLP-1 agonists, for diabetes, or for both diabetes and weight management, are classified in A10S. | r2024 |

| | | |
|-------------|---|-------|
| A10H | SULPHONYLUREA ANTIDIABETICS Includes plain products containing chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, tolbutamide, etc. For combinations of sulphonylureas with other antidiabetics, use the most appropriate specific combination class. For combinations with vitamins only, classify as plain sulphonylureas. | I2009 |
| A10J | BIGUANIDE ANTIDIABETICS | I2009 |
| A10J1 | Biguanide antidiabetics, plain Includes plain products containing buformin, metformin, phenformin, etc. | I2009 |
| A10J2 | Biguanide and sulphonylurea antidiabetic combinations Includes combinations of biguanides with sulphonylureas. | I2009 |
| A10J9 | Biguanide antidiabetic combinations, other Includes combinations of biguanides with other antidiabetics where there is no other appropriate class. For combinations with vitamins only, classify as plain biguanides. | I2009 |
| A10K | GLITAZONE ANTIDIABETICS Products containing glitazars, eg carfloglitazar, saroglitazar etc, are classified in A10X9. | r2024 |
| A10K1 | Glitazone antidiabetics, plain Includes plain products containing pioglitazone, rosiglitazone, troglitazone, etc. | I2009 |
| A10K2 | Glitazone and sulphonylurea antidiabetic combinations Includes combinations of glitazones with sulphonylureas. | I2009 |
| A10K3 | Glitazone and biguanide antidiabetic combinations Includes combinations of glitazones with biguanides. | I2009 |
| A10K9 | Glitazone antidiabetic combinations, other Includes combinations of glitazones with other antidiabetics where there is no other appropriate class. Combinations of a glitazone with a biguanide and also a sulphonylurea are classified in A10K9. Combinations of a glitazone with a biguanide and also a DPP-IV inhibitor are classified in A10N9. | I2009 |
| A10L | ALPHA-GLUCOSIDASE INHIBITOR ANTIDIABETICS Includes plain products containing acarbose, miglitol, voglibose, etc. | I2009 |

| | | |
|-------------|--|-------|
| A10M | GLINIDE ANTIDIABETICS | I2009 |
| A10M1 | Glinide antidiabetics, plain Includes plain products containing repaglinide, nataglinide, mitiglinide, etc. | I2009 |
| A10M3 | Glinide and biguanide antidiabetic combinations Includes combinations of glinide antidiabetics with biguanides. | I2009 |
| A10M9 | Glinide antidiabetic combinations, other Includes combinations of glinide antidiabetics with other antidiabetics where there is no other appropriate class. | I2009 |
| A10N | DPP-IV INHIBITOR ANTIDIABETICS | I2009 |
| A10N1 | DPP-IV inhibitor antidiabetics, plain Includes plain products containing denagliptin, saxagliptin, sitagliptin, vildagliptin, etc. | I2009 |
| A10N3 | DPP-IV inhibitor and biguanide antidiabetic combinations Includes combinations of DPP-IV inhibitors with biguanides. | I2009 |
| A10N9 | DPP-IV inhibitor antidiabetic combinations, other Includes combinations of DPP-IV inhibitors with other antidiabetics where there is no other appropriate class. Combinations of a DPP-IV with a glitazone and a biguanide are classified in A10N9. Combinations of a DPP-IV inhibitor with an SGLT2 inhibitor and a biguanide are classified in A10P9. | r2020 |
| A10P | SGLT2 INHIBITOR ANTIDIABETICS | R2016 |
| A10P1 | SGLT2 inhibitor antidiabetics, plain Includes plain products containing SGLT2 inhibitors, eg canagliflozin, dapagliflozin, empagliflozin, etc. Products containing SGLT2 inhibitors for diabetes and also for heart failure and/or chronic kidney disease are classified here. Products containing SGLT2 inhibitors for diabetes and/or cardiovascular risk are classified here. | r2024 |
| A10P3 | SGLT2 inhibitor and biguanide antidiabetic combinations Includes combinations of SGLT2 inhibitors with biguanides. | I2016 |
| A10P5 | SGLT2 inhibitor and DPP-IV inhibitor antidiabetic combinations Includes combinations of SGLT2 inhibitors with DPP-IV inhibitors. | I2017 |

| | | |
|-------|---|-------|
| A10P9 | SGLT2 inhibitor antidiabetic combinations, other Includes combinations of SGLT2 inhibitors with other oral antidiabetics where there is no other appropriate class. Combinations of an SGLT2 inhibitor with a DPP-IV inhibitor and a biguanide are classified here. | r2020 |
| A10S | GLP-1 AGONIST ANTIDIABETICS Includes glucagon-like peptide 1 receptor agonist antidiabetics, eg exenatide, liraglutide, lixisenatide. Combinations of GLP-1 agonist antidiabetics with human insulins or analogues are classified in A10C9. Products containing oral forms of GLP-1 agonists for diabetes are classified here. Products containing dual GIP and GLP-1 agonists for diabetes are classified here. Products containing GLP-1 agonists, or dual GIP/GLP-1 agonists, for weight management only are classified in A8A. Products containing GLP-1 agonists, or dual GIP/GLP-1 agonists, for both diabetes and weight management are classified here. | r2024 |
| A10X | OTHER DRUGS USED IN DIABETES | R2010 |
| A10X1 | Antidiabetic multitherapy combination products Includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. For example, rosiglitazone in combination with simvastatin. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity. For example, metformin in combination with sibutramine. | I2010 |
| A10X9 | Other drugs used in diabetes Includes products used for the treatment of diabetes, as well as adjuvant therapy in the treatment and prevention of conditions associated with or developing from diabetes. Includes aldose reductase inhibitors (eg epalrestat, tolrestat), guar gum and glucose products specifically intended for the treatment of hypoglycaemic shock. Includes products containing glucokinase activator antidiabetics, eg dorzagliatin. Includes products containing glitazars, eg carfloglitazar, saroglitazar etc. Teas and other herbal extracts used as adjuvant therapy are classified here. | r2024 |

| | | |
|-------------|--|-------|
| A16 | OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | |
| A16A | OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Includes all alimentary tract and metabolism products not classified elsewhere. Oral preparations containing procaine are classified in A13A1. Products containing one or more oral antidiabetic substances in combination with one or more substances from a cardiovascular class where the aim is to treat both the diabetes and the cardiovascular condition are classified in A10X1. Products containing teduglutide for short bowel syndrome are classified here. Products containing prebiotic fibre for gut health and/or immune support are classified here. Products containing lumasiran for primary hyperoxaluria type 1 are classified in G4X. Products containing elapegademase or pegademase for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified in L3A9. | r2024 |

| | | |
|-------------|--|-------|
| B2D | BLOOD COAGULATION PRODUCTS | r2024 |
| | Products used to treat haemophilia are classified in the appropriate fourth level according to the blood factors or blood fractions whose dysfunction they correct, eg by replacement, substitution, gene therapies etc. | |
| B2D1 | Factor VIII, including substitutes | r2024 |
| | Products for haemophilia A containing factors, substitutes or gene therapies, eg valoctocogene roxaparvovec, are classified here. Includes antihæmophilic globulin A, emcizumab, etc. Products containing von Willebrand factor only are classified in B2D9. | |
| B2D2 | Factors II, VII, IX and X | r2024 |
| | Products for haemophilia B containing factors, substitutes or gene therapies, eg etranacogene dezaparvovec, fidanacogene elaparvovec etc, are classified here. Includes antihæmophilic globulin B and prothrombin complex. | |
| B2D3 | Haemophilia anti-inhibitor products | r2024 |
| | Products for haemophilia A and/or haemophilia B with inhibitors are classified here. Includes activated FVII (FVIIa), aPCC (activated prothrombin complex concentrate), concizumab, eptacog alfa, etc. | |
| B2D4 | Factor XIII | |
| B2D5 | Fibrinogen | |
| B2D6 | Fresh frozen plasma and antihæmophilic plasma | |
| B2D7 | Cohn-Fraction I | |
| B2D8 | Platelet concentrates | |
| B2D9 | Other blood fractions | r2024 |
| | Includes products containing von Willebrand factor (single ingredient). | |
| | Products containing fitusiran for haemophilia are classified here. | |
| B2E | PLATELET-ENHANCING PRODUCTS | R2023 |
| B2E1 | Thrombopoietin agonists | I2023 |
| | Includes products containing thrombopoietin agonists for thrombocytopenia, eg avatrombopag, eltrombopag, hetrombopag olamine, lusutrombopag, romiplostim, thrombopoietin, etc. | |
| B2E9 | Platelet-enhancing products, other | I2023 |
| | Includes products for thrombocytopenia containing fostamatinib, oprelvekin, etc. | |

| | | |
|------------|---|-------|
| B2F | <p data-bbox="317 136 847 170">TISSUE SEALING PREPARATIONS</p> <p data-bbox="317 210 1394 356">Includes products imitating the physiological process of fibrin formation which are used for tissue sealing, haemostasis and support of wound healing. Products containing thrombin/collagen for the prevention of bleeding prior to implantation of ICDs/pacemakers are classified here.</p> | r2016 |
|------------|---|-------|

| | | |
|-------------|---|-------|
| B3 | ANTI-ANAEMIC PREPARATIONS | |
| B3A | HAEMATINICS, IRON AND ALL COMBINATIONS | |
| | Any products which contain iron, irrespective of other ingredients (for example, folic acid, vitamin B12, etc.) are classified in B3A. | |
| B3A1 | Plain iron | |
| | This class also includes preparations containing ingredients for better absorption and/or reducing agents, such as ascorbic acid, as well as combinations with cobalt. | |
| B3A2 | Iron combination products | R1993 |
| | Includes all other iron combinations including those containing liver extract and/or folic acid. | |
| B3B | LIVER EXTRACTS AND COMBINATIONS WITH B12 | |
| | Includes liver extracts, excluding all preparations not used for anaemia. Oral B12 with intrinsic factor allocated is classified in B3B. | |
| B3C | ERYTHROPOIETIN PRODUCTS | R1995 |
| B3D | HIF-PH INHIBITORS | I2020 |
| | Includes products containing HIF-PH (hypoxia-inducible factor prolyl hydroxylase) inhibitors (for example, daprodustat, enarodustat, molidustat, roxadustat, vadadustat, etc) for the treatment of anaemia in chronic kidney disease. | |
| B3X | OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID | r2024 |
| | Folinic acid products with more than one indication are classified in V3D. | |
| | Includes products containing betibeglogene autotemcel for beta thalassaemia, luspatercept for anaemia associated with beta thalassaemia, sutimlimab for inhibition of haemolysis in cold agglutinin disease. | |
| | Products for sickle cell disease (SCD), including those for haemolytic anaemia associated with SCD, eg voxelotor, are classified in B6X. | |

| | | |
|------------|---|-------|
| B6 | ALL OTHER HAEMATOLOGICAL AGENTS | R1996 |
| B6A | Out of use; can be reused from 1999. | D1996 |
| B6B | HYALURONIDASE | |
| B6C | Out of use | D2020 |
| B6D | HEREDITARY ANGIOEDEMA PRODUCTS Includes products containing eg C1 inhibitor/conestat alfa, ecallantide, icatibant, etc when indicated for hereditary angioedema. | I2015 |
| B6X | OTHER HAEMATOLOGICAL AGENTS Includes haemins. Excluded are those preparations used in the treatment of veins and haemorrhoids (C5) and preparations for dermatological use (D3A). Products containing fostamatinib or oprelvekin for the prevention of severe thrombocytopenia are classified in B2E9. Products containing complement inhibitors: for paroxysmal nocturnal haemoglobinuria (PNH) only are classified here; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for multiple conditions are classified in L4X. Products for sickle cell disease (SCD), including those for haemolytic anaemia associated with SCD, eg voxelotor, are classified here. Products containing mitapivat for pyruvate kinase deficiency (PKD) are classified here. | r2024 |

| | | |
|------------|---|-------|
| C1D | CORONARY THERAPY EXCLUDING CALCIUM ANTAGONISTS AND NITRITES <p>This group includes all other products indicated for coronary insufficiency and angina pectoris. It includes benziodarone, capobenic acid, carbocromen, cinepazet, cinepazic acid, cloridarol, dilazep, dipyridamole, efloxate, etafenone, fenalcomine, flosequinan, hexobendine, imolamine, ivabradine, medibazine, molsidomine, oxyfedrin, trimetazidine, visnadine. Combinations with nitrites are included in C1E and with beta-blockers are included in C7B.</p> | R2007 |
| C1E | NITRITES AND NITRATES <p>This group includes all nitrites and analogous products and combinations if they are indicated for angina pectoris. Combinations of nitrites with cardiac glycosides are classified in C1A2 and combinations with beta-blockers in C7B.</p> | |
| C1F | POSITIVE INOTROPIC AGENTS <p>This group includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol.</p> | R1994 |
| C1X | ALL OTHER CARDIAC PREPARATIONS <p>This group includes substances such as alprostadil, crateagus glycosides, creatinolphosphate, phosphocreatinine, levocarnitine and ubidecarenone. Combination products are only classified in this group if they contain a substance which is not in the C group.</p> <p>Products containing alprostadil for peripheral arterial occlusive disease only are classified in C4A1. Products containing alprostadil for erectile dysfunction only are classified in G4E9. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified here.</p> <p>Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified in N7X. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified here. Products containing tafamidis for both TAP and TAC are classified in N7X.</p> <p>Products containing mavacamten for hypertrophic cardiomyopathy are classified here.</p> | r2024 |

| | | |
|-------------|--|-------|
| C4 | CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS | |
| C4A | CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS This group includes all products (including citicoline) which are mainly recommended for cerebral vascular diseases or peripheral circulatory disorders excluding venous diseases. Combination products are only classified in this group if they do not belong to group C1-C3, C7-C11. | R2005 |
| C4A1 | Cerebral and peripheral vasotherapeutics excluding calcium antagonists with cerebral activity Products containing phenoxybenzamine alone, and indicated either for hypertension or BPH are classified here. Products containing cinepazide alone and for vasodilation are classified here. Products containing beperminogene perplasmid for improvement of limb ischaemia are classified here. Products containing alprostadil for peripheral arterial occlusive disease only are classified here. Products containing alprostadil for erectile dysfunction only are classified in G4E9. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified in C1X. Products containing clazosentan for cerebral haemorrhage are classified here. | r2024 |
| C4A2 | Calcium antagonists with cerebral activity Includes, bencyclane, cinnarizine, cyclandelate, flunarizine and nimodipine. | R1993 |

| | | |
|-------------|--|-------|
| C6 | OTHER CARDIOVASCULAR PRODUCTS | R2017 |
| C6A | Out of use; can be reused from 2020. | D2017 |
| C6B | PULMONARY ARTERIAL HYPERTENSION (PAH) PRODUCTS | I2017 |
| C6B1 | Endothelin receptor antagonist PAH products Includes products for pulmonary arterial hypertension (PAH) containing endothelin receptor antagonists such as ambrisentan, bosentan, macitentan, sitaxentan, etc. | I2017 |
| C6B2 | PDE5 inhibitor PAH products Products containing PDE5 inhibitors and indicated only for pulmonary arterial hypertension (PAH) are classified here. Products containing PDE5 inhibitors and indicated for both erectile dysfunction and PAH are classified in G4E1. | I2017 |
| C6B3 | Prostacyclin agonist PAH products Products containing prostacyclin agonists (eg iloprost, selexipag, treprostinil) and indicated for pulmonary hypertension only, are classified here. Products containing epoprostenol are all classified here. Products containing prostacyclin agonists and indicated for platelet aggregation inhibition are classified in B1C4. Products containing prostacyclin agonists for PAH and other conditions are classified in B1C4. | I2017 |
| C6B9 | Pulmonary arterial hypertension (PAH) products, other Includes other products for PAH, eg those containing soluble guanylate synthase stimulators such as riociguat. | I2017 |
| C6X | OTHER CARDIOVASCULAR PRODUCTS This group includes all other products that are mainly recommended for diseases of the cardiovascular system and that cannot be classified in groups C1-C6B or C7-11. Potassium and magnesium aspartate are usually classified here. In certain cases when these compounds are indicated as mineral supplements, they are classified in A12. Products containing icatibant for hereditary angioedema are classified in B6D. Products containing SGLT2 inhibitors for diabetes and/or cardiovascular risk are classified in A10P1. | r2024 |

| | | |
|-------------|--|-------|
| C10 | LIPID-REGULATING/ANTI-ATHEROMA PREPARATIONS | R2005 |
| | Excludes products intended for weight reduction. | |
| C10A | CHOLESTEROL AND TRIGLYCERIDE REGULATING PREPARATIONS | r2010 |
| | Includes all products regulating cholesterol and triglycerides only. Combinations with products of group C4 should be classified here. Combinations with oral antidiabetic substances are classified in A10X1. | |
| C10A1 | Statins (HMG-CoA reductase inhibitors) | R2006 |
| | Includes atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin. | |
| | Combinations of statins with ezetimibe are classified in C10C. | |
| C10A2 | Fibrates | I1997 |
| | Includes bezafibrate, bezafibrate, ciprofibrate, clofibrate, clofibrade, etofibrate, fenofibrate, gemfibrozil, simfibrate. | |
| C10A3 | Ion-exchange resins | I1997 |
| | Includes cholestyramine, colestipol, polidexide. | |
| C10A4 | PCSK9 inhibitors | I2016 |
| | Includes proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, eg alirocumab, evolocumab. | |
| C10A9 | All other cholesterol/triglyceride regulators | r2024 |
| | Includes ezetimibe, probucol, tiadenol, pyridinolcarbamate and all other products excluding those in C10B. | |
| | Combinations of ezetimibe with statins or with bempedoic acid are classified in C10C. | |
| | Nicotinic acid derivatives if indicated in this area are classified here, eg acipimox. | |
| | Products containing volanesorsen for familial chylomicronaemia syndrome (FCS) are classified here. | |
| | Products containing evinacumab for homozygous familial hypercholesterolaemia are classified here. | |

| | | |
|------------|---|---------------------|
| D5 | NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS <p>Includes products for psoriasis, hyperkeratosis, ichthyosis, eczema, dermatitis, seborrhoea. Psoralens are classified here when used for inflammatory conditions. Excluded from this class are combinations with antibacterials (D6A), antifungals (D1A) and products specifically indicated in acne (D10A). Sulphur baths which contain other substances besides sulphur and are not used for dermatological purposes, are classified in M2A.</p> | <u>r2019</u> |
| D5A | TOPICAL ANTIPSORIASIS PRODUCTS <p>Includes products containing substances such as tar, coal tar, ichthammol, dithranol, psoralens, salicylic acid for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing corticosteroids in combination with coal tar or salicylic acid for psoriasis are classified here. These products may also be for other inflammatory skin conditions.</p> <p>Includes products consisting of coal tar or calcipotriol, alone or in combination, when indicated for psoriasis.</p> | r2019 |
| D5B | SYSTEMIC ANTIPSORIASIS PRODUCTS <p>Includes products for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing brodalumab, ixekizumab, secukinumab or ustekinumab and indicated for psoriasis and also other non-skin conditions, eg arthritis, are classified in L4C. Psoriatic arthritis is defined as a skin condition.</p> <p>Apremilast is classified here if only for psoriatic skin conditions. Products containing apremilast for multiple conditions are classified in L4X.</p> <p>Products containing deucravacitinib for psoriasis are classified here.</p> | r2024 |
| D5X | OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS <p>Includes nonsteroidal products for inflammatory skin disorders which are not indicated for psoriasis. Specific topical immunomodulators for dermatitis are classified here.</p> <p>Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here. Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified in L1X8. Products containing topical fluorouracil for actinic keratosis are classified in L1B.</p> <p>Products containing dupilumab for atopic dermatitis only are classified here. Products containing dupilumab for both atopic dermatitis and asthma are classified in L4C.</p> <p>Products containing nemolizumab for pruritus associated with atopic dermatitis are classified here.</p> | r2024 |

| | |
|--|--|
| <p>Products containing ligelizumab for urticaria are classified here.</p> <p>Products containing JAK inhibitors, eg ruxolitinib, for atopic dermatitis and/or other inflammatory skin disorders, eg alopecia areata, vitiligo, etc, are classified here. Products containing JAK inhibitors for inflammatory skin disorders and other non-dermatological conditions are classified in L4D.</p> | |
|--|--|

| | | |
|-------------|---|-------|
| D11 | OTHER DERMATOLOGICAL PREPARATIONS | |
| D11A | OTHER DERMATOLOGICAL PREPARATIONS <p>Includes medicated shampoos, medicated soaps, scalp lotions (other than in D5A, D1A3, D7B, D8A, D10A). Products for pigmentation disorders, androgenetic alopecia, systemic products for the treatment of dermatological conditions, anti-corn agents (plasters, tinctures, including products with salicylic acid especially formulated for warts, corns and calluses etc), products to reduce and improve the appearance of scars, and hair-restorers are classified in this group.</p> <p>Products containing finasteride 1mg and for androgenetic alopecia are classified here. Products containing finasteride 5mg and for BPH are classified in G4C3.</p> <p>Products containing JAK inhibitors, eg ruxolitinib, for atopic dermatitis and/or other inflammatory skin disorders, eg alopecia areata, vitiligo, etc, are classified in D5X.</p> <p>Products containing extracts of chamomile are classified in D3A.</p> <p>Psoralens, when used for inflammatory conditions, are classified in D5.</p> <p>Products containing sirolimus gel for tuberous sclerosis are classified here.</p> | r2024 |

| | | |
|------|---|-------|
| G2X9 | <p>Other gynaecologicals</p> <p>Specific products included in this class are non-hormonal anti-inflammatories (eg benzydamine) which are indicated specifically to treat gynaecological conditions. Includes lubricants for intimate vaginal use only. Includes products (lactogogues) for the promotion of milk production.</p> <p>Products containing paroxetine (7.5mg daily) or fezolinetant, and indicated for menopausal vasomotor symptoms are classified here.</p> <p>Products containing bremelanotide or flibanserin and indicated for hypoactive sexual desire disorder (HSDD) in women are classified here.</p> <p>Products containing omega-3 fatty acids for use as supplements during pregnancy and when breastfeeding are classified in V3X.</p> | r2024 |
|------|---|-------|

| | | |
|------------|--|-------|
| G4 | UROLOGICALS | |
| G4A | URINARY ANTI-INFECTIVES AND ANTISEPTICS | |
| G4A1 | Urinary antibacterials <p>This group includes those products containing an antibacterial where the only indication is for urinary tract infections. Sulphonamides are generally classified in J3 and other antibacterials in J1. All trimethoprim formulations are classified in J1E. Combinations with halogenated or non-halogenated quinolones are classified in G4A2.</p> | r2009 |
| G4A2 | Urinary non-halogenated quinolones <p>Includes products containing non-halogenated quinolones which are only indicated for urinary tract infections. Systemic products containing halogenated quinolones (plain) are classified in J1G. Combinations of halogenated or non-halogenated quinolones with other substances (including antibacterials) and indicated for urinary tract infections are classified in G4A2.</p> | R2009 |
| G4A3 | Out of use; can be reused from 2010. | D2007 |
| G4A9 | Other urinary antiseptics <p>Includes such products as nitrofurantoin and methenamine. Irrigating solutions are classified in Group K.</p> | I2007 |
| G4B | Out of use; can be reused from 2010. | D2007 |
| G4C | BPH (BENIGN PROSTATIC HYPERTROPHY) PRODUCTS | R2007 |
| G4C1 | Out of use | D2012 |
| G4C2 | BPH alpha-adrenergic antagonists, plain <p>Includes products containing alpha-adrenergic antagonists, such as alfuzosin, tamsulosin. Products containing terazosin, for BPH or hypertension, are classified here. Products containing doxazosin are classified in C2A2. Products containing indoramin, for BPH or hypertension, are classified in C2A2, or in N2C9 if indicated for migraine.</p> | r2015 |
| G4C3 | BPH 5-alpha testosterone reductase inhibitors (5-ARI), plain <p>Includes products containing 5-alpha testosterone reductase inhibitors (5-ARI), such as dutasteride and finasteride.</p> <p>Products containing finasteride 5mg and for BPH are classified here. Products containing finasteride 1mg and for androgenetic alopecia are classified in D11A.</p> | r2024 |

| | | |
|-------------|---|-------|
| G4E | ERECTILE DYSFUNCTION PRODUCTS Includes products for the treatment of male impotence. | r2015 |
| G4E1 | Erectile dysfunction products, PDE5 inhibitors Includes products containing PDE5 inhibitors, eg avanafil, mirodenafil, sildenafil, tadalafil, udenafil, vardenafil, etc, when indicated for the treatment of erectile dysfunction. Products containing sildenafil (oral 20mg) or tadalafil and indicated for pulmonary arterial hypertension (PAH) only are classified in C6B2. Products containing tadalafil and indicated for both erectile dysfunction and PAH are classified here. Products indicated for erectile dysfunction that contain a PDE5 inhibitor in combination with other substances are classified here. Products containing a PDE5 inhibitor in combination with other substances, and indicated for erectile dysfunction as well as other conditions, are classified here. Products containing PDE5 inhibitors for BPH only are classified in G4C9. | r2021 |
| G4E9 | Erectile dysfunction products, others Includes products containing eg alprostadil, apomorphine, etc when indicated for the treatment of erectile dysfunction. Products containing alprostadil for peripheral arterial occlusive disease only are classified in C4A1. Products containing alprostadil for erectile dysfunction only are classified here. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified in C1X. In addition, includes products that contain substances of natural origin for erectile dysfunction. Products that do not contain a PDE5 inhibitor and are indicated for erectile dysfunction, together with other urological conditions, are classified here. | r2021 |
| G4X | ALL OTHER UROLOGICAL PRODUCTS Includes products containing local anaesthetics used specifically for premature ejaculation. Products for erectile dysfunction are classified in G4E. Products for both erectile dysfunction and other urological conditions are also classified in G4E. Products for improving general sexual performance (not specifically erectile dysfunction) are classified here. Products containing sparsentan for kidney conditions, eg IgA nephropathy, are classified here. Products containing complement inhibitors: for kidney conditions only, eg IgA nephropathy, are classified here; for paroxysmal nocturnal haemoglobinuria (PNH) | r2024 |

| | | |
|--|--|--|
| | <p>only are classified in B6X; for multiple conditions are classified in L4X.</p> <p>Products containing lumasiran for primary hyperoxaluria type 1 are classified here.</p> | |
|--|--|--|

| | | |
|------------|--|-------|
| J6E | POLYVALENT IMMUNO-GLOBULINS - INTRAMUSCULAR | R2006 |
| | The action of these homologous substances is based on a wide spectrum of antibodies mainly belonging to the IgG fraction. Includes subcutaneous as well as intramuscular forms. | |
| J6F | POLYVALENT IMMUNOGLOBULINS - COMBINATION MODULATION - MAINLY INTRAMUSCULAR | |
| | These homologous immunoglobulins include: - those whose action is not exclusively based on the IgG fraction. - those which exist in combination with other substances. - those which cause a modulation of the immune response. | |
| J6G | SPECIFIC IMMUNOGLOBULINS - ANTIBACTERIAL | r2022 |
| | These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. Products for post-exposure prophylaxis are classified here. Products for both post-exposure prophylaxis and for treatment are classified here. | |
| J6G1 | Tetanus immunoglobulin | |
| J6G2 | Pertussis immunoglobulin | |
| J6G9 | Other antibacterial immunoglobulins | |
| | This group includes diphtheria, streptococci, staphylococci and pseudomonas immunoglobulins. | |
| J6H | SPECIFIC IMMUNOGLOBULINS - ANTIVIRAL | r2024 |
| | These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. Products for prevention/post-exposure prophylaxis are classified here. Products for both prevention/post-exposure prophylaxis and for treatment are classified here. | |
| J6H1 | Mumps immunoglobulin | |
| J6H2 | Measles immunoglobulin | |
| J6H3 | Rubella immunoglobulin | |
| J6H4 | Hepatitis immunoglobulin | |
| J6H5 | Rabies immunoglobulin | |

| | | |
|------|--|-------|
| J6H9 | <p>Other antiviral immunoglobulins</p> <p>This group includes varicella-zoster, tick-borne meningo-encephalitis, poliomyelitis, cytomegaly, herpes and COVID-19 immunoglobulins. Products containing palivizumab for the prevention of respiratory syncytial virus (RSV) infections are classified here.</p> <p>Monoclonal antibodies for prevention/post-exposure prophylaxis, and for both prevention/post-exposure prophylaxis and treatment of COVID-19 are classified here. Monoclonal antibodies for treatment only of COVID-19 are classified in J5B6.</p> | r2024 |
|------|--|-------|

| | | |
|------------|---|-------|
| J7E | VIRAL VACCINES Includes separate classes for vaccines against only one viral group. For vaccines against a combination of bacteria or viruses, see J7B. | r2018 |
| J7E1 | Influenza vaccines | I2014 |
| J7E2 | Varicella vaccines | I2014 |
| J7E3 | HPV (human papillomavirus) vaccines | I2014 |
| J7E4 | Hepatitis vaccines | I2014 |
| J7E5 | Rotavirus vaccines | I2014 |
| J7E6 | Coronavirus vaccines Includes vaccines against COVID-19. | I2021 |
| J7E9 | All other viral vaccines Includes all other vaccines against one viral group, eg Japanese encephalitis, measles, mumps, polio, respiratory syncytial virus (RSV), rubella, rabies, smallpox, tick-borne encephalitis, yellow fever. | r2024 |
| J7F | PROTOZOAL VACCINES Includes separate classes for vaccines against only one protozoal group. For vaccines against a combination of a protozoal group and/or other organisms, see J7B. | I2018 |
| J7F1 | Malaria vaccines | I2018 |
| J7F9 | All other protozoal vaccines | I2018 |
| J7X | ALL OTHER VACCINE-LIKE PRODUCTS Includes products containing infectious agents and/or their derivatives, eg lysates and extracts of bacteria, that are not strictly considered vaccines. | r2018 |

| | | |
|-------------|--|-------|
| L | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | R1994 |
| L1 | ANTINEOPLASTICS Includes all preparations mainly indicated for the treatment of cancers and all packs specifically produced for use in anticancer therapy eg special anticancer packs of antibiotics. The definition of neoplasms includes both malignant and benign conditions. | r2024 |
| L1A | ALKYLATING AGENTS Includes nitrogen mustard analogues (eg chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, prednimustine, trofosfamide), ethylene imines (eg altretamine (hexamethylmelamine), carboquone, thiotepa, triaziquone), nitrosoureas (eg bendamustine, carmustine, fotemustine, lomustine, semustine, streptozocin), alkyl sulfonates (eg busulfan, mannosulfan, mitolactol, treosulfan), triazenes and analogues. Dacarbazine is classified in this group. | R2003 |
| L1B | ANTIMETABOLITES Includes folic acid analogues (eg methotrexate), pyrimidine analogues (eg capecitabine, carmofur, cytarabine, fluorouracil, tegafur) and purine analogues (eg fludarabine, mercaptopurine, tioguanine). Methotrexate can also be classified in M1C for rheumatic conditions or in D for dermatological conditions. Products containing topical fluorouracil for actinic keratosis are classified here. | r2016 |
| L1C | PLANT-BASED ANTINEOPLASTICS Includes products that contain plant-derived alkaloids, terpenes, lignans etc, or their derivatives/analogues. Combination products containing substances from two fourth level classes of L1C are classified in the higher level class, eg a combination of a camptothecin with a podophyllotoxin is classified in L1C3. | R2016 |
| L1C1 | Vinca alkaloid antineoplastics Includes products containing alkaloids (or their derivatives/analogues) that are derived from <i>Cantharanthus roseus</i> (Madagascan periwinkle), eg vinblastine, vincristine, vindesine, vinflunine, vinorelbine, etc. | I2016 |
| L1C2 | Taxane antineoplastics Includes products containing diterpenes (or their derivatives/analogues) that are derived from species of <i>Taxus</i> (yew), eg cabazitaxel, docetaxel, paclitaxel, etc. | I2016 |

| | | |
|-------------|---|-------|
| L1G | MONOCLONAL ANTIBODY ANTINEOPLASTICS Antineoplastic monoclonal antibodies against protein kinases are classified here and not in L1H. Products containing antibody drug conjugates (ADCs) are classified in the appropriate fourth level, according to the antibody target. If there is not a class for the target, the product is classified in L1G9. Products containing bispecific antibodies are classified in the appropriate fourth level, where a target class is available. If there is not a class for either target, the product is classified in L1G9. If there is a separate class for each target, the product is classified in L1G9. | r2024 |
| L1G1 | Monoclonal antibody antineoplastics, CD20 Includes products containing obinutuzumab, ofatumumab, rituximab, rituximab with hyaluronidase, etc. Products containing ofatumumab for multiple sclerosis only are classified in N7A. | r2022 |
| L1G2 | Monoclonal antibody antineoplastics, VEGF/VEGFR Includes products containing bevacizumab, ramucirumab, etc. | I2019 |
| L1G3 | Monoclonal antibody antineoplastics, HER-2 Includes products containing margetuximab, pertuzumab, trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine, etc. | r2021 |
| L1G4 | Monoclonal antibody antineoplastics, EGFR Includes products containing cetuximab, necitumumab, nimotuzumab, panitumumab, etc. | I2019 |
| L1G5 | Monoclonal antibody antineoplastics, PD-1/PD-L1 Includes products containing atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, pembrolizumab, tislelizumab, etc. Products containing a combination of nivolumab with relatlimab are classified in L1G9. Products containing PD-1/CTLA-4 bispecific antibody antineoplastics, eg cadonilimab, are classified here. | r2024 |

| | | |
|------|--|-------|
| L1G9 | <p>Monoclonal antibody antineoplastics, other</p> <p>Includes antibodies with other targets including other CD targets, CTLA-4 (ipilimumab), etc. Products containing PD-1/CTLA-4 bispecific antibody antineoplastics, eg cadonilimab, are classified in L1G5. Products containing bispecific antibodies are classified in the appropriate fourth level, where a target class is available. If there is not a class for either target, the product is classified here. If there is a separate class for each target, the product is classified here.</p> <p>Includes antibody drug conjugates (ADCs) if not classified with the target class (brentuximab vedotin, gemtuzumab ozogamicin, inotuzumab ozogamicin). Includes radio-labelled antibodies (ibritumomab tiuxetan, tositumomab iodine-131).</p> <p>Includes alemtuzumab, blinatumomab, brentuximab vedotin, catumaxomab, daratumumab, dinutuximab, elotuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumab ozogamicin, ipilimumab, mogamulizumab, olaratumab, racotumomab, rovalpituzumab tesirine, sabatolimab, siltuximab, tositumomab, tositumomab iodine-131, etc.</p> <p>Includes products containing a combination of nivolumab with relatlimab. Products containing nivolumab alone are classified in L1G5.</p> <p>Products containing alemtuzumab and indicated for cancer only are classified here. Products containing alemtuzumab and indicated for multiple sclerosis are classified in N7A.</p> | r2024 |
| L1H | <p>PROTEIN KINASE INHIBITOR ANTINEOPLASTICS</p> <p>Antineoplastic monoclonal antibodies against protein kinases are classified in L1G.</p> | R2019 |
| L1H1 | <p>Protein kinase inhibitor antineoplastics, BCR-ABL</p> <p>Includes products containing bosutinib, dasatinib, imatinib, nilotinib, ponatinib, radotinib, etc.</p> | I2019 |
| L1H2 | <p>Protein kinase inhibitor antineoplastics, EGFR</p> <p>Includes products containing afatinib, dacomitinib, erlotinib, gefitinib, icotinib, olmutinib, osimertinib, varlitinib, etc.</p> | I2019 |
| L1H3 | <p>Protein kinase inhibitor antineoplastics, ALK</p> <p>Includes products containing alectinib, brigatinib, ceritinib, crizotinib, lorlatinib, etc.</p> | I2019 |

| | | |
|------|---|-------|
| L1H4 | Protein kinase inhibitor antineoplastics, BRAF/MEK Includes products containing binimetinib, cobimetinib, dabrafenib, encorafenib, selumetinib, trametinib, vemurafenib, etc. | I2019 |
| L1H5 | Protein kinase inhibitor antineoplastics, CDK 4/6 Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here. | I2019 |
| L1H6 | Protein kinase inhibitor antineoplastics, BTK Includes products containing acalabrutinib, ibrutinib, tirabrutinib, zanubrutinib, etc. | I2021 |
| L1H7 | Protein kinase inhibitor antineoplastics, JAK Includes products containing fedratinib, momelotinib, pacritinib, ruxolitinib, etc that are primarily for cancer. Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions (eg topical forms of ruxolitinib for atopic dermatitis), and in M1 if only for musculoskeletal conditions. Products containing JAK inhibitors to treat multiple immune conditions are classified in L4D. | I2024 |
| L1H9 | Protein kinase inhibitor antineoplastics, other Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2 etc. Pi3K inhibitors are included even though they are lipid kinase inhibitors and not strictly protein kinase inhibitors. Includes axitinib, cabozantinib, erdafitinib, everolimus, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, nintedanib, pazopanib, regorafenib, rivoceranib (apatinib), sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, etc. Products containing nintedanib for idiopathic pulmonary fibrosis only are classified in R7D. Products containing nintedanib for cancer only are classified here. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified in R7D. Products containing alpelisib for PIK3CA-related overgrowth spectrum (PROS) are classified here. Products containing KRAS inhibitors, eg adagrasib, sotorasib, etc, for cancer are classified in L1X9. | r2024 |
| L1J | PROTEASOME INHIBITOR ANTINEOPLASTICS | I2018 |

| | | |
|------------|--|-------|
| L1K | <p>Includes products containing proteasome inhibitors for neoplasms, eg bortezomib, carfilzomib, ixazomib, etc.</p> <p>LIDOMIDE ANTINEOPLASTICS</p> | I2022 |
| L1L | <p>Includes products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers.</p> <p>Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are classified in L4X.</p> <p>PARP INHIBITOR ANTINEOPLASTICS</p> <p>Includes products containing niraparib, olaparib, rucaparib, talazoparib, veliparib, etc.</p> <p>Products containing combinations of niraparib with abiraterone are classified here.</p> | r2024 |

| | | |
|------|--|-------|
| L1X9 | <p>All other antineoplastics</p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, pentostatin, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Includes products containing cancer gene therapies eg nadofaragene firadenovec, talimogene laherparepvec, etc.</p> <p>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</p> <p>Products containing BCG vaccine for cancer are classified here; those for general immunostimulation are classified in L3A9. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p> <p>Products containing miltefosine for skin metastases of breast cancer are classified here. Products containing miltefosine for leishmaniasis are classified in P1G.</p> <p>Products containing interferons, eg ropeginterferon alfa 2b, for cancer only are classified here.</p> <p>Products containing tacelecleucel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD) are classified here.</p> <p>Products containing KRAS inhibitors, eg adagrasib, sotorasib, etc, for cancer are classified here.</p> | r2024 |
|------|--|-------|

| | | |
|------------|---|-------|
| L2 | CYTOSTATIC HORMONE THERAPY | I1994 |
| | Includes all types of hormones used primarily in the treatment of cancers, eg adrenocorticoids, progestogens, oestrogens, anti-oestrogens and androgens. | |
| L2A | CYTOSTATIC HORMONES | I1994 |
| L2A1 | Cytostatic oestrogens | I1994 |
| L2A2 | Cytostatic progestogens | I1994 |
| L2A3 | Cytostatic gonadotrophin-releasing hormone analogues | r2020 |
| | Buserelin, deslorelin, goserelin, nafarelin, leuporelin and triptorelin are classified here. When these substances are not used as cytostatics they are classified in H1C. Products containing gonadotrophin-releasing hormone analogues for cancer and also for other conditions are classified here. | |
| L2A9 | Other cytostatic hormones | I1994 |
| | Includes substances such as drostanolone, testolactone. | |
| L2B | CYTOSTATIC HORMONE ANTAGONISTS | I1994 |
| L2B1 | Cytostatic anti-oestrogens | r2024 |
| | Includes substances such as tamoxifen, mepitiostane, epitiostanol, toremifene. Products containing selective oestrogen receptor degraders (SERDs), eg elacestrant, fulvestrant, etc, for cancer are classified here. | |
| L2B2 | Cytostatic anti-androgens | r2024 |
| | Includes substances such as flutamide, nilutamide. Cyproterone acetate (50 mg; injectable forms) is classified here. Products containing combinations of niraparib with abiraterone are classified in L1L. | |
| L2B3 | Cytostatic aromatase inhibitors | r2019 |
| | Includes aminoglutethamide, anastrozole, exemestane, formestane, letrozole. | |
| | Products containing both ribociclib and letrozole are classified in L1H5. | |
| L2B9 | Other cytostatic hormone antagonists | r2024 |
| | Products containing relugolix for cancer are classified here. Products containing relugolix (single ingredient) for uterine fibroids or endometriosis are classified in H1C3. Products containing relugolix in combination with oestrogens and progestogens for uterine fibroids are classified in G3X. | |

| | | |
|------------|--|-------|
| L3 | IMMUNOSTIMULATING AGENTS | I1994 |
| L3A | IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS | R2004 |
| L3A1 | Colony-stimulating factors Includes ancestim, empegfilgrastim, filgrastim, lenograstim, molgramostim, pegfilgrastim, sargramostim. | r2018 |
| L3A9 | All other immunostimulating agents excluding interferons Includes cridanimod, glatiramer acetate, interleukin-2, picibanil. <i>Corynebacterium parvum</i> and levamisole are classified here when used as immunostimulants. Products containing BCG vaccine for cancer are classified in L1X9; those for general immunostimulation are classified here. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6. Products containing elapegademase or pegademase for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified here. | r2021 |
| L3B | INTERFERONS | r2024 |
| | Products containing interferons (with or without ribavirin) for multiple indications are classified in L3B. Products containing interferons (with or without ribavirin) for hepatitis only are classified in J5D1. Products containing interferons, eg ropeginterferon alfa 2b, for cancer only are classified in L1X9. | |
| L3B1 | Interferons, alpha | I1994 |
| L3B2 | Interferons, beta Products containing beta interferons and indicated for multiple sclerosis only are classified in N7A. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified here. | R2017 |
| L3B3 | Interferons, gamma | I1994 |
| L3B9 | Interferons, non-specified | I1994 |

| | | |
|------------|--|-------|
| L4 | IMMUNOSUPPRESSANTS | R2010 |
| L4A | Out of use; can be reused from 2013. | D2010 |
| L4B | ANTI-TNF PRODUCTS Products containing anti-TNF substances are classified here, eg adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab. These products can be indicated for multiple conditions, eg rheumatoid arthritis, Crohn's disease, psoriasis. Products containing apremilast for psoriatic conditions only are classified in D5B. Products containing apremilast for multiple conditions are classified in L4X. | r2020 |
| L4C | INTERLEUKIN INHIBITORS Includes products containing interleukin inhibitors, eg basiliximab, canakinumab, daclizumab, rilonacept. Includes interleukin inhibitors indicated for the treatment of rejection in organ transplants and for auto-inflammatory diseases such as CAPS (cryopyrin-associated periodic syndromes). Products containing tocilizumab or anakinra and indicated for arthritic conditions are classified in M1C. Products containing tocilizumab or anakinra and indicated for arthritic and also other conditions are classified in M1C. Products containing brodalumab, ixekizumab, secukinumab or ustekinumab and indicated for skin conditions such as psoriasis and also other non-skin conditions, eg rheumatoid arthritis, are classified here. Psoriatic arthritis is defined as a skin condition. Products containing daclizumab and indicated for use in kidney transplantation are classified here. Products containing daclizumab and indicated for multiple sclerosis and other conditions are classified in N7A. Products containing interleukin inhibitors for asthma only are classified in R3M. Products containing interleukin inhibitors for asthma and any of the following conditions, EGPA (eosinophilic granulomatosis with polyangiitis), chronic rhinosinusitis with nasal polyposis, nasal polyps, hypereosinophilic syndrome are classified in R3M. Products containing dupilumab for atopic dermatitis are classified in D5X. Products containing dupilumab for both atopic dermatitis and asthma are classified here. Products containing levilimab for use in COVID-19 are classified here. | r2023 |

| | | |
|------------|--|-------|
| L4D | <p>JAK INHIBITORS</p> <p>Includes products containing JAK inhibitors, eg baricitinib, filgotinib, tofacitinib, upadacitinib, etc. These products are indicated for multiple conditions, eg rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, etc.</p> <p>Products containing JAK inhibitors primarily for cancer are classified in L1H7.</p> <p>Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions (eg topical forms of ruxolitinib for atopic dermatitis), and in M1 if only for musculoskeletal conditions.</p> | I2024 |
| L4X | <p>OTHER IMMUNOSUPPRESSANTS</p> <p>Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p>Includes eg azathioprine, cyclosporin, muromonab-cd3, mycophenolate mofetil, tacrolimus – unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X. Products containing antilymphocyte or antithymocyte immunoglobulins are classified here.</p> <p>Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p> <p>Products containing apremilast for psoriatic skin conditions only, are classified in D5B. Psoriatic arthritis is defined as a skin condition. Products containing apremilast for multiple conditions are classified here.</p> <p>Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in L1K. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1K. Products containing thalidomide for erythema nodosum leprosum only are classified here.</p> <p>Products containing leflunomide for multiple conditions are classified here. Products containing leflunomide for rheumatoid arthritis only are classified in M1C.</p> <p>Products containing complement inhibitors: for paroxysmal nocturnal haemoglobinuria (PNH) only are classified in B6X; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for multiple conditions are classified here.</p> <p>Corticosteroids are not classified here.</p> | r2024 |

| | | |
|------------|--|-------|
| M1C | <p data-bbox="316 136 911 170">SPECIFIC ANTI-RHEUMATIC AGENTS</p> <p data-bbox="316 212 1393 392">This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosalicylates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p data-bbox="316 434 1393 501">Azathioprine is in L4X. Products containing methotrexate for rheumatic conditions are classified here; otherwise methotrexate is classified in LIB or in D.</p> <p data-bbox="316 544 1129 577">Products containing anti-TNF substances are classified in L4B.</p> <p data-bbox="316 620 1393 757">Products containing baricitinib, filgotinib, tofacitinib or upadacitinib (JAK inhibitors), and indicated for rheumatoid arthritis only, are classified here. Products containing baricitinib, filgotinib, tofacitinib or upadacitinib for multiple conditions are classified in L4D.</p> <p data-bbox="316 799 1393 902">Products containing leflunomide, and indicated for rheumatoid arthritis only, are classified here. Products containing leflunomide for multiple conditions are classified in L4X.</p> <p data-bbox="316 945 1393 1124">Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here. Products containing tocilizumab or anakinra and indicated for both arthritic and other conditions are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</p> <p data-bbox="316 1167 927 1200">Psoriatic arthritis is defined as a skin condition.</p> | r2024 |
|------------|--|-------|

| | | |
|-------------|---|-------|
| M5 | OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM | |
| M5A | Out of use; can be reused from 1996. | D1993 |
| M5B | BONE CALCIUM REGULATORS | R2002 |
| | Calcitonin products are classified in H4A. Products containing calcium only are classified in A12A and fluoride products are classified in A12C2. | |
| M5B1 | Out of use; can be reused from 2010. | D2007 |
| M5B2 | Out of use; can be reused from 2010. | D2007 |
| M5B3 | Bisphosphonates for osteoporosis and related disorders | r2024 |
| | Includes products indicated and used mainly for osteoporosis and Paget's disease of bone, eg those containing alendronic acid, etidronic acid, ibandronic acid, risedronic acid, zoledronic acid, when indicated for these conditions. Combinations of bisphosphonates with calcium, calcitriol or colecalciferol are also classified here. | |
| M5B4 | Bisphosphonates for tumour-related calcium disorders | I2007 |
| | Includes products indicated and used mainly for tumour-related calcium disorders (eg hypercalcaemia of malignancy) eg those containing clodronic acid, etidronic acid, ibandronic acid, pamidronic acid, zoledronic acid when indicated for these conditions. | |
| M5B9 | Other bone calcium regulators | I2002 |
| | Includes other specific products which are used for osteoporosis (eg ipriflavone). | |

| | | |
|------------|--|-------|
| M5X | ALL OTHER MUSCULOSKELETAL PRODUCTS <p>Includes all other products for disorders of the musculoskeletal system not classified elsewhere. Includes musculoskeletal products containing substances such as cartilage extract, chondroitin, etc. Products containing chondroitin and glucosamine alone or in combination with other substances are classified here. Combinations of glucosamine with nonsteroidal anti-inflammatories are classified in M1A2. Topical glucosamine and chondroitin products are classified in M2A.</p> <p>Includes hydroquinine indicated for restless leg syndrome.</p> <p>Includes herbal products used for musculoskeletal pain.</p> <p>Products containing burosumab for X-linked hypophosphataemia are classified here.</p> <p>Products containing mexiletine for non-dystrophic myotonic disorders are classified here; products containing mexiletine for cardiac arrhythmias are classified in C1B .</p> <p>Products containing diclofenamide for primary periodic paralysis are classified here. Products containing diclofenamide for glaucoma are classified in S1E1. Products containing diclofenamide for diuretic use are classified in C3A9.</p> <p>Products containing vamorolone for Duchenne muscular dystrophy (DMD) are classified here.</p> <p>Products containing efgartigimod, rozanolixizumab, or zilucoplan for myasthenia gravis only are classified here.</p> | r2024 |
|------------|--|-------|

| | | |
|------------|---|-------|
| N3 | ANTI-EPILEPTICS | |
| N3A | ANTI-EPILEPTICS Also includes products for non-epileptic convulsions, eg in pregnancy. Products containing clonazepam are classified here. Products containing gabapentin or pregabalin for epilepsy or neuropathic pain or both are classified here. Products containing gabapentin or pregabalin for neuropathic pain and fibromyalgia are classified here. Products containing mirogabalin for neuropathic pain only are classified in N2B. | r2024 |

| | | |
|-------------|--|-------|
| N7D | ANTI-ALZHEIMER PRODUCTS | I1998 |
| N7D1 | Anti-Alzheimer products, cholinesterase inhibitors Includes eg donepezil, galantamine, rivastigmine and tacrine. | R2003 |
| N7D9 | All other anti-Alzheimer products Includes all other products specifically used for Alzheimer's disease. | I1998 |
| N7E | DRUGS USED IN ALCOHOL DEPENDENCE Includes acamprosate, calcium carbimide, disulfiram. Naltrexone when used in alcohol dependence is classified here. | R2002 |
| N7F | DRUGS USED IN OPIOID DEPENDENCE Includes naltrexone, except when used in alcohol dependence (use N7E). | R2002 |
| N7X | ALL OTHER CNS DRUGS Includes parasympathetic agents. Benzodiazepine antagonists such as flumazenil are classified here. Atomoxetine is included in the class. Products containing gabapentin or pregabalin are classified in N3A if indicated for neuropathic pain, both neuropathic pain and epilepsy, or both neuropathic pain and fibromyalgia. Products containing pilocarpine and indicated for both dry mouth and dry eye are classified here. Products indicated for multiple sclerosis are classified in N7A. Products containing fampridine for improvement in walking in multiple sclerosis are classified here. Products indicated for amyotrophic lateral sclerosis (ALS) are classified here. Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified here. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified in C1X. Products containing tafamidis for both TAP and TAC are classified here. Products containing inebilizumab or satralizumab for neuromyelitis optica spectrum disorder (NMOSD) are classified here. | r2024 |